Fujian Haixi New Pharmaceutical Co Ltd (Ticker: 2637 HK) is a China-based biotechnology company engaged in the R&D, production, and commercialization of generic and innovative drugs across therapeutic areas such as digestive, cardiovascular, endocrine, nervous system, and inflammatory diseases. The company plans to list on the Hong Kong Stock Exchange (Main Board) on October 17, 2025, offering 11.5 million new shares at an expected price range of HKD 69.88–86.40 per share, to raise approximately HKD 993.6 million (about $127.7 million).

The offering is fully primary, with no secondary shares. CMB International Capital Ltd and Huatai Financial Holdings (Hong Kong) Ltd serve as joint sponsors, alongside underwriters including CMBC Securities, Futu Securities International, and China Industrial Securities International. The company intends to allocate 82% of the IPO proceeds toward R&D and production capacity expansion, 8% toward brand promotion and business development, and 10% toward working capital and strategic acquisitions.